New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:31 EDTBIIBBiogen receives notification of PDUFA date extension for Plegridy
Biogen Idec announced that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application for marketing approval of PLEGRIDY, a subcutaneous pegylated interferon candidate for relapsing forms of multiple sclerosis. The PDUFA date has been extended by three months, which is the standard extension period. The FDA has indicated that the extension of the PDUFA date is required to allow additional time for review of the application. The agency has not asked for additional studies.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
10:58 EDTBIIBDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 15, 2015
09:31 EDTBIIBAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 13, 2015
07:32 EDTBIIBBiogen names Matt Griffiths as CIO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use